Brad Bourgeois
Nurse Practitioner · Gretna, LANPI 1982066783
Payments from drug & device makers
Across 87 payments — averaging $18.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$257
- Bayer$236
- AbbVie$155
- Corcept Therapeutics$122
- Angiodynamics, Inc.$122
- VBI Vaccine (delaware) Inc.$116
- plus $567 from 14 others
What the payments were for
- Food & beverage$1,575100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 18 | $257 |
| Bayer | 16 | $236 |
| AbbVie | 7 | $155 |
| Corcept Therapeutics | 6 | $122 |
| Angiodynamics, Inc. | 1 | $122 |
| VBI Vaccine (delaware) Inc. | 5 | $116 |
| Pfizer | 5 | $83 |
| AstraZeneca | 5 | $81 |
| Abbott | 3 | $68 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $54 |
| Novo Nordisk | 3 | $47 |
| Merck | 3 | $42 |
| Xeris Pharmaceuticals, Inc. | 2 | $41 |
| Boston Scientific | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Cipher Pharmaceuticals US LLC | 1 | $22 |
| Cranial Technologies, Inc | 1 | $19 |
| Boehringer Ingelheim | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Cardiovascular Systems Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,575 in reported general payments places this provider in the 75th percentile of 969 nurse practitioner providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 26 | $26,949 |
| TrulicityDulaglutide | 17 | $24,365 |
| OzempicSemaglutide | 23 | $21,887 |
| Lidocaine | 12 | $895 |
| Azelastine Hcl | 15 | $531 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $417 |
| Atorvastatin Calcium | 48 | $381 |
| Fluticasone Propionate | 18 | $311 |
| Gabapentin | 21 | $256 |
| Glimepiride | 16 | $243 |
| Metformin Hcl | 22 | $226 |
| Montelukast Sodium | 12 | $221 |
| Omeprazole | 11 | $216 |
| Metoprolol Succinate | 15 | $205 |
| Testosterone Cypionate | 23 | $200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $257 | $51,31443 claims |
| Novo NordiskOzempic | $47 | $21,88723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 969 nurse practitioner providers in Louisiana.
Other nurse practitioner in Gretna
- Karen DeshotelLafayette$264K
- Christopher ManuelKaplan$145K
- Tammy BennettShreveport$99K
- Jessica BordelonHammond$78K
- Teri DugganBossier City$67K
- Matt LandryLafayette$50K
- Cynthia CobbLafayette$48K
- Ellen GentileWest Monroe$31K
- Reghan LittlepageAlexandria$24K
- April WoodrowOpelousas$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.